Pancreatic Cancer Research

ResearcherNational Cheng Kung University HospitalActive in the last 2 years

Ting‐Kai Liao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4742-8066; OpenAlex author ID A5023726510. Sources: ClinicalTrials.gov.

Their work

Papers
6
Trials
1
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 6

  1. Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors. Co-author DOI 10.1007/s13304-026-02686-8↗
  2. A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy. Co-author DOI 10.1097/js9.0000000000005024↗
  3. Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1002/cnr2.70267↗
  4. Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study in T… Co-author DOI 10.1007/s00432-025-06353-0↗
  5. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
  6. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗

Trials 1

  1. Multimodal Therapy Impact on Pancreatic Cancer Survival Study director NCT06938906↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ping‐Jui Su · 6 shared papers, 2022–2026 · strength 1.53
  2. Yan‐Shen Shan · 6 shared papers, 2022–2026 · strength 1.53
  3. Ying‐Jui Chao · 3 shared papers, 2022–2025 · strength 0.60
  4. Yung‐Yeh Su · 3 shared papers, 2022–2026 · strength 0.57
  5. Nai‐Jung Chiang · 2 shared papers, 2022–2023 · strength 0.29
  6. Chien‐Jui Huang · 2 shared papers, 2022–2023 · strength 0.29
  7. Li‐Tzong Chen · 2 shared papers, 2022–2023 · strength 0.29
  8. Hui‐Jen Tsai · 1 shared paper, 2022 · strength 0.12
  9. Yan-Shen Shan · 1 shared trial, 2011 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.